<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488929</url>
  </required_header>
  <id_info>
    <org_study_id>TC-5619-23-CRD-003</org_study_id>
    <nct_id>NCT01488929</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targacept Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targacept Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Negative symptoms and cognitive dysfunction in schizophrenia (CDS) are core features of
      schizophrenia. These negative symptoms and cognitive deficits have a devastating impact on
      the function, employment, and social interactions of patients with schizophrenia. Medications
      used to treat schizophrenia (e.g. atypical antipsychotics) do not improve negative symptoms
      or CDS. TC-5619 is being developed for use as an add-on therapy in combination with atypical
      antipsychotics to treat patients with negative symptoms and CDS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Scale for Assessment of Negative Symptoms (SANS)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Cogstate Schizophrenia Battery (CSB)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in UCSD Performance Based Skills Assessment, brief version (UPSA-Brief)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">603</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Negative Symptoms</condition>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>5 mg TC-5619</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of 5 mg TC-5619 will be administered orally once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg TC-5619</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of 50 mg TC-5619 will be administered orally once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet of placebo will be administered orally once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5619</intervention_name>
    <arm_group_label>5 mg TC-5619</arm_group_label>
    <arm_group_label>50 mg TC-5619</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of schizophrenia, per DSM-IV-TR criteria, as aided by the MINI International
             Neuropsychiatric Interview

          2. Controlled schizophrenia, on stable dose of an approved atypical antipsychotic for at
             least 2 months prior to screening. Approved refers to regulatory approval in the
             country of use.

          3. Stable schizophrenia as documented by lack of psychiatric hospitalization for 2 months
             prior to Screening (social admissions for the convenience of the subject allowed)

          4. Clinical history of stable psychotic symptoms for 1 month prior to Screening.

          5. Stable positive symptoms of schizophrenia for 4 weeks prior to Day 1, as shown by
             score â‰¤ 4 on PANSS for items related to delusion, hallucination, conceptual
             disorganization, and unusual thought content, at Screening and at Day 1.

          6. Sum &gt; 20 for the 7 items in the Negative Symptoms subscale of the PANSS.

          7. Calgary Depression Schizophrenia Scale (CDSS) score &lt; 6.

          8. Simpson Angus Scale score &lt; 12.

          9. Outpatient with stable housing, and significant presence of an informant who is not a
             group home resident.

        Exclusion Criteria:

          1. Diagnosis of schizoaffective or schizophreniform disorders within 1 year prior to
             Screening.

          2. Significant risk of suicide or attempted suicide in the 12 months before screening, or
             of danger to themselves or others.

          3. Change in dosing of atypical antipsychotic within 2 months of Screening.

          4. Treatment with electroconvulsive therapy (ECT) within 12 months of Screening.

          5. Treatment with mood stabilizers, antidepressants, anxiolytics (short-acting hypnotics
             permitted), anticholinergics, or more than 1 antipsychotic within 1 month prior to
             Screening.

          6. Treatment within 1 month prior to Screening with cognition-affecting agents other than
             the above (e.g. CNS stimulants).

          7. History within past 6 months of screening of alcohol or illicit drug abuse.

          8. Use of smoking cessation therapy within 1 month prior to Screening.

          9. Positive urine drug screen except when related to prescribed short-acting
             benzodiazepines and opiates recently prescribed for an episode of acute pain (e.g.,
             dental extraction).

         10. History of significant other major or unstable neurological, neurosurgical (e.g. head
             trauma), metabolic, hepatic, renal, hematological, pulmonary, cardiovascular,
             gastrointestinal, or urological disorder.

         11. History of myocardial infarction based on medical history or electrocardiogram (ECG)
             findings at screening.

         12. History of seizure disorder.

         13. Type 1 diabetes mellitus.

         14. Type 2 diabetes mellitus that requires medication (diet-controlled allowed, with HbA1C
             &lt; 7.3).

         15. Body Mass Index (BMI) &gt; 35.

         16. Uncontrolled hypothyroidism, vitamin B12 or folic acid deficiency.

         17. Current TB or known systemic infection (e.g., HBV, HCV, HIV).

         18. Clinically significant lab or ECG abnormality that could be a safety issue in the
             study, including QTcF &gt; 450 for males and &gt;470 for females.

         19. Men, or women of child-bearing potential, who are unwilling or unable to use accepted
             methods of birth control as specified in Section 4.4.4

         20. Women with a positive pregnancy test, or who are lactating.

         21. Participated in another clinical trial within 3 months prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P Walling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collaborative Neuroscience Network, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, Inc</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavorial Research Specialists</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apostle Clinical Trials, Inc</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research Center</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excell Research, Inc.</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNRI</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34749</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Behavioral Health Hospital</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Group</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Psychiatric Associates - Midwest Reserch Group</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PsychCare Consultants Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Medical Research</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavorial Clinic Research, Inc.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, L.P.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Department of Psychiatry</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Centre, Department of Psychiatry</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharma4Trial Kft.</name>
      <address>
        <city>Gyongyos</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pecs, Department of Psychiatry</name>
      <address>
        <city>Pecs</city>
        <zip>7600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George Hospital, Department of Psychiatry</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Emergency Clinical Hospital of Arad</name>
      <address>
        <city>Arad</city>
        <state>Arad County</state>
        <zip>310022</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMDTA Neomed</name>
      <address>
        <city>Brasov</city>
        <state>Brasov County</state>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Lorentina 2102 SRL</name>
      <address>
        <city>Targoviste</city>
        <state>Dambovita County</state>
        <zip>130081</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatry Clinical Hospital Craiova, Psychiatry Department</name>
      <address>
        <city>Craiova</city>
        <state>Dolj County</state>
        <zip>200473</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Emergency Central Military Hospital, Dept. of Psychiatry</name>
      <address>
        <city>Bucharest</city>
        <zip>010816</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Clinical Psychiatric Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Research Institute of Psychiatry</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menthal Health Research Center of the RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizhniy Novgorod Regional Psychoneurological Hospital # 1</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603152</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizhny Novgorod Region State Budgetary Institution of Healthcare &quot;Clinical Psychiatric Hospital #1 of Nizhny Novgorod&quot;</name>
      <address>
        <city>Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municiple Healthcare Institution (City Clinical Hospital #2)</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Public Healthcare Institution (City Psychiatric Hospital #7)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Public Healthcare Institution (Saint Nicholas Psychiatric Hospital)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Public Healthcare Institution (City Psychiatric Hospital #4)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191119</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Healthcare Institution (City Psychiatric Hospital #6)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg Research Psychoneurogical Institute</name>
      <address>
        <city>St.Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of Russian Academy of Medical Sciences</name>
      <address>
        <city>Tomsk</city>
        <zip>634014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl State Medical Academy, Department of Psychiatry</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Healthcare Institution (Sverdlovsk Regional Clinical Psychiatric Hospital)</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre &quot;Dr Dragisa Misovic&quot;, Clinic of Psychiatry</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Clinic of Psychiatry</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Mental Health</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Nis, Psychiatric Clinic</name>
      <address>
        <city>Gornja Toponica</city>
        <zip>18202</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Kragujevac, Psychiatric Clinic</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Special Hospital for Psychiatric Diseases &quot;Sveti Vracevi&quot;</name>
      <address>
        <city>Vojvodina</city>
        <zip>23330</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crimean State Medical University (Dept. of Psychiatry)</name>
      <address>
        <city>Simferopol</city>
        <state>Autonomous Republic of Crimea</state>
        <zip>95006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odesa Regional Psychiatric Hospital #2</name>
      <address>
        <city>Odesa</city>
        <state>Kominternivskyy District</state>
        <zip>67513</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk Regional Clinical Hospital</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk State Medical Academy, Dept. of Psychiatry</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk National Medical University (Regional Clinical Psychiatric Hospital)</name>
      <address>
        <city>Donetsk</city>
        <zip>83008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology, Psychiatry and Narcology AMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv Regional Clinical Psychiatric Hospital N 3</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Station Railway Clinical Hospital # 1 of the STBA &quot;South-Western Railway&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lugansk State Medical University</name>
      <address>
        <city>Lugansk</city>
        <zip>91045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odesa Regional Psychoneurological Dispensary</name>
      <address>
        <city>Odesa</city>
        <zip>65014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ukrainian Medical Stomatological Academy, Dept. of Psychiatry</name>
      <address>
        <city>Poltava</city>
        <zip>36013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsya National Medical University, Dept. of Psychiatry &amp; Narcology</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <disposition_first_submitted>May 11, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 11, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 3, 2015</disposition_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

